A pivotal role for Mcl-1 in Bortezomib-induced apoptosis (Q40102590)

17 September 2017

title

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis (English)

1 reference

17 September 2017

0 references

Podar K

1 reference

17 September 2017

Gouill SL

1 reference

17 September 2017

Zhang J

1 reference

17 September 2017

Opferman JT

1 reference

17 September 2017

Zorn E

1 reference

17 September 2017

Tai YT

1 reference

17 September 2017

Hideshima T

1 reference

17 September 2017

Amiot M

1 reference

17 September 2017

Chauhan D

1 reference

17 September 2017

Harousseau JL

1 reference

17 September 2017

Anderson KC

1 reference

17 September 2017

language of work or name

English

0 references

publication date

23 July 2007

1 reference

17 September 2017

1 reference

17 September 2017

1 reference

17 September 2017

1 reference

17 September 2017

page(s)

721-731

1 reference

MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Proteasome inhibitor therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

DNA and its associated processes as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Mcl-1 regulation and its role in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Optimal detection of apoptosis by flow cytometry depends on cell morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

inferred from DOI database lookup

7 January 2021

based on heuristic

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

inferred from DOI database lookup

7 January 2021

based on heuristic

Unraveling MCL-1 degradation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210679

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1210679

1 reference

Dimensions Publication ID

17 September 2017

1011802176

0 references

1 reference